A Mitochondria‐Targeted Nanozyme Platform for Multi‐Pathway Tumor Therapy via Ferroptosis and Cuproptosis Regulation
Advanced Science · 2025-09 · 12 (36)
DOI: 10.1002/advs.202417616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 25.06.2025. Verfasst von Chenguang Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 310018, P. R. China. Hauptthemen laut MEDLINE: Ferroptosis, Copper, Mitochondria, Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Transition metal‐based nanotherapeutics, such as chemodynamic therapy and ferroptosis‐ or cuproptosis‐induced strategies, hold great potential for cancer treatment. Copper‐ and iron‐based nanozymes enhance reactive oxygen species (ROS) generation and regulate metal ion homeostasis, driving ferroptosis and cuproptosis. However, simultaneous delivery of copper and iron ions and the role of mitochondria‐targeted copper in inducing cuproptosis remain underexplored. Here, a dual‐functional nano‐heterojunction platform, MIL‐Cu 1.8 S‐TPP/FA, is reproted, integrating iron‐ and copper‐based components for synergistic ferroptosis and cuproptosis induction. Mitochondria‐targeted Cu 1.8 S nanodots demonstrated high biocompatibility and efficiently induced cuproptosis by disrupting mitochondrial iron‐sulfur proteins. Combined with MIL‐88B, the iron‐based metal‐organic framework, the MIL‐Cu 1.8 S heterojunction exhibited enhanced ROS catalytic activity, confirmed by density functional theory (DFT) analysis, with improved H 2 O 2 adsorption and lower energy barriers for peroxidase (POD)‐like reactions. The dual‐targeting MIL‐Cu 1.8 S‐TPP/FA nanoplatform effectively delivered copper ions to mitochondria and iron ions to tumor cells, modulating key ferroptosis‐ and cuproptosis‐related markers, such as GPX4, GSH, FDX‐1, and HSP70. The platform synergistically combined photothermal effects with multi‐pathway cell death mechanisms, achieving significant anti‐tumor efficacy in vitro and in vivo. This study underscores the therapeutic potential of synchronously delivering copper and iron ions and highlights mitochondria‐targeted strategies in advancing multi‐modal cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 310018, P. R. China.
- Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, Zhejiang Sci-Tech University, Hangzhou, 310018, P. R. China.
ORCID-Profile: Chenguang Liu
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Liu, C., Guo, L., Cheng, Y., Gao, J., Pan, H., Zhu, J., Li, D., Jiao, L., & Fu, C. (2025). A Mitochondria‐Targeted Nanozyme Platform for Multi‐Pathway Tumor Therapy via Ferroptosis and Cuproptosis Regulation. Advanced Science, 12(36). https://doi.org/10.1002/advs.202417616
Vancouver
Liu C, Guo L, Cheng Y, Gao J, Pan H, Zhu J, et al. A Mitochondria‐Targeted Nanozyme Platform for Multi‐Pathway Tumor Therapy via Ferroptosis and Cuproptosis Regulation. Advanced Science. 2025;12(36). doi:10.1002/advs.202417616
BibTeX
@article{Liu2025,
author = {Liu, Chenguang and Guo, Lingxiao and Cheng, Yuying and Gao, Jingjie and Pan, Hanling and Zhu, Jiayi and Li, Danting and Jiao, Liqing and Fu, Caiyun},
title = {A Mitochondria‐Targeted Nanozyme Platform for Multi‐Pathway Tumor Therapy via Ferroptosis and Cuproptosis Regulation},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {36},
doi = {10.1002/advs.202417616}
}
EUVIMED